mricor Medical Systems Inc (ASX:IMR) chair and CEO Steve Wedan speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.
12 August 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.
Imricor Medical Systems, Inc. is pleased to announce that it has signed a Master Purchasing Agreement with Sana Einkauf & Logistik GmbH of Ismaning Germany (Sana). Sana is the largest Group Purchasing Organisation (GPO) in Germany, with 600 cooperating hospitals and medical institutions across Germany and Switzerland. Approximately 80 of these sites perform cardiac ablations and are therefore potential Imricor customers.
Imricor Medical Systems, Inc. (ASX:IMR) today announces that it has received CE mark approval for its Vision-MR Ablation Catheter and Vision-MR Dispersive Electrode. This follows earlier CE mark approval for Imricor to place its Advantage-MR EP Recorder/Stimulator System on the market in the European Union. Imricor is the first and only company to offer cardiac ablation in the MRI environment.